Experience matters in cell and gene therapy trials Using experienced-based best practices and documented tools, ICON has conducted over 63 CGT trials across multiple therapeutic areas from haematology-oncology to rare and orphan diseases. With 400+ team members dedicated to cell and gene therapy, we support preclinical, regulatory and commercial positioning as well as translational and clinical development. We understand that cell and gene therapy trials must be delivered differently. Because there are no handbooks and few standards, experience matters. ICONplc.com/CGThttps://www.iconplc.com/therapeutics/cell-and-gene-therapies/index.xml